Please login to the form below

Not currently logged in
Email:
Password:

Dennis O'Brien

This page shows the latest Dennis O'Brien news and features for those working in and with pharma, biotech and healthcare.

Lucid Group acquires digital and creative agency Bluedog

Lucid Group acquires digital and creative agency Bluedog

Bluedog brings a “key piece of the jigsaw” to Lucid, commented Lucid’s CEO Dennis O’Brien, referring to the company’s skills in digital design, motion graphics, video development and ... a “perfect match” says O’Brien.

Latest news

  • Signal strength Signal strength

    The best communications programmes start by identifying the patient outcomes they want to improve and work backwards from there,” says Dennis O’Brien, CEO, Lucid Group. ... says Dennis O’Brien.

  • The Communiqué Awards at 20: Dennis O’Brien The Communiqué Awards at 20: Dennis OBrien

    Lucid's CEO on the Awards' enduring influence

  • Lucid strikes £11m investment deal with equity firm LDC Lucid strikes £11m investment deal with equity firm LDC

    Lucid’s founders Dennis O’Brien and Jan Steele will continue to lead the business. ... O’Brien said: “We felt the time was right to bring on board a strategic partner, and in LDC we have an experienced investor with a strong track record in the

  • The beauty and the beast of customer experience The beauty and the beast of customer experience

    It is hard to do this from the bottom up,” says Dennis O'Brien, CEO, Lucid Group. ... Dennis. “You need to understand what their current experience is, what their touchpoints are, what happens at those touchpoints and, ultimately, how can you improve

  • A New View A New View

    Marketing has always been about adding value to a client or a customer,” says Dennis O'Brien, CEO, Lucid Group. ... It's the right way,” says Dennis. “Today's dynamic marketplace requires more than just identifying core customers and hitting them

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • The social dilemma: is it time for pharma to join the party?

    Welcome to the world of social media in pharma, 2019-style. The words of Dennis O’Brien, CEO at Lucid Group, provide a mischievous metaphor to which we can all relate: ... The question is: why? Pay to party. Dennis O'Brien. “Pharma isn’t yet

  • The first, my last, my everything The first, my last, my everything

    It’s making progress, but there’s a long way to go. “We’ve got to get much closer to patients,” said Dennis O’Brien, CEO, Lucid Group. ... We need to get over it.”. Progress, said Dennis, may require a fundamental shift in mindset.

  • Measures for measures Measures for measures

    Pharma widely accepts that it struggles to measure digital marketing effectiveness – but perhaps it’s starting from the wrong place,” said Dennis O’Brien, CEO, Lucid Group. ... said Dennis O’Brien.

  • Trust me, I’m from pharma Trust me, I’m from pharma

    compliance against regulation in the core areas where pharma has tripped up in the past, says Dennis O’Brien, CEO, Lucid Group.

  • Patient outcomes in practice: delivering value that transforms lives Patient outcomes in practice: delivering value that transforms lives

    Dennis O’Brien is Lucid co-founder and CEO; Louise Verrall is managing director, Lucid Partners.

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 33 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics